ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis

Area of Science:

• Neuroimmunology
• Hematology

Background:

• ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) is crucial for preventing microvascular thrombosis and inflammation.
• Reduced ADAMTS13 levels are observed in multiple sclerosis (MS) patients.
• The role of ADAMTS13 in MS disease progression was investigated using a mouse model.

Purpose of the Study:

• To determine the therapeutic potential of ADAMTS13 in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.
• To evaluate the impact of ADAMTS13 on disease course, demyelination, and inflammatory infiltration in the EAE model.

Main Methods:

• Female C57BL/6 mice were induced with EAE using MOG35-55 peptide.
• Mice received ADAMTS13 or vehicle treatment in preventive and therapeutic settings.
• Clinical deficits, demyelination, inflammatory cell infiltration, VWF expression, and blood-spinal cord barrier (BSCB) integrity were assessed.

Main Results:

• ADAMTS13 activity was suppressed in EAE mice.
• ADAMTS13 treatment ameliorated EAE, reducing demyelination and inflammatory cell infiltration in the spinal cord.
• ADAMTS13 administration reduced VWF levels and inhibited BSCB breakdown, but did not affect peripheral leukocytes.

Conclusions:

• ADAMTS13 treatment effectively ameliorates inflammatory responses, demyelination, and disease progression in the EAE mouse model.
• These findings suggest that ADAMTS13 holds potential as a therapeutic strategy for multiple sclerosis.